Literature DB >> 26786627

Computational approach to understanding the mechanism of action of isoniazid, an anti-TB drug.

Lingaraja Jena1, Pranita Waghmare1, Supriya Kashikar2, Satish Kumar1, Bhaskar C Harinath3.   

Abstract

Tuberculosis (TB) is an ancient disease caused by Mycobacterium tuberculosis (MTB), which remains a major cause for morbidity and mortality in several developing countries. Most drug-resistant MTB clinical strains are resistant to isoniazid (INH), a first-line anti-TB drug. Mutation in KatG, a catalase-peroxidase, of MTB is reported to be a major cause of INH resistance. Normally upon activation by KatG, INH is converted to an active intermediate which has antimycobacterial action in MTB. This INH intermediate in the presence of NADH forms INH-NAD adduct which inhibits inhA (2-trans-enoyl-acyl carrier protein reductase) of MTB, thus blocking the synthesis of mycolic acid, a major lipid of the mycobacterial cell wall. In this docking study, the high binding affinity of INH-NAD adduct towards InhA was observed in comparison with INH alone. In this study, two resistant mutants of KatG (S315T and S315N) were modeled using Modeller9v10 and docking analysis with INH was performed using AutoDock4.2 and the docking results of these mutants were compared with the wild type KatG. Docking results revealed the formation of a single hydrogen (H) bond between the secondary amine nitrogen (-NH) of INH with Thr or Asn residues in place of Serine at 315 position of KatG mutant strains respectively, whereas in the case of the wild type, there was no H-bond formation observed between INH and Ser315. The H-bond formation may prevent free radical formation by KatG in mutant strains thus the development of resistance to the drug. This in silico evidence may implicate the basis of INH resistance in KatG mutant strains.
Copyright © 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug resistance; InhA; Isoniazid; KatG; Mutation

Year:  2014        PMID: 26786627     DOI: 10.1016/j.ijmyco.2014.08.003

Source DB:  PubMed          Journal:  Int J Mycobacteriol        ISSN: 2212-5531


  10 in total

1.  Novel mutations detected from drug resistant Mycobacterium tuberculosis isolated from North East of Thailand.

Authors:  Ei Phoo Thwe; Wises Namwat; Porntip Pinlaor; Kulrattana Rueangsak; Arunnee Sangka
Journal:  World J Microbiol Biotechnol       Date:  2021-10-13       Impact factor: 3.312

2.  Synergism of Plant Compound With Traditional Antimicrobials Against Streptococcus spp. Isolated From Bovine Mastitis.

Authors:  Natasha L Maia; Mariana de Barros; Leandro L de Oliveira; Silvia A Cardoso; Marcelo H Dos Santos; Fabio A Pieri; Teodorico C Ramalho; Elaine F F da Cunha; Maria A S Moreira
Journal:  Front Microbiol       Date:  2018-06-06       Impact factor: 5.640

3.  Synthesis and In Vitro Antimycobacterial Activity of Novel N-Arylpiperazines Containing an Ethane-1,2-diyl Connecting Chain.

Authors:  Tomáš Goněc; Ivan Malík; Jozef Csöllei; Josef Jampílek; Jiřina Stolaříková; Ivan Solovič; Peter Mikuš; Stanislava Keltošová; Peter Kollár; Jim O'Mahony; Aidan Coffey
Journal:  Molecules       Date:  2017-11-30       Impact factor: 4.411

Review 4.  Psychotropics and the Microbiome: a Chamber of Secrets….

Authors:  Sofia Cussotto; Gerard Clarke; Timothy G Dinan; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2019-02-26       Impact factor: 4.530

5.  Real-time monitoring of live mycobacteria with a microfluidic acoustic-Raman platform.

Authors:  Vincent O Baron; Mingzhou Chen; Björn Hammarstrom; Robert J H Hammond; Peter Glynne-Jones; Stephen H Gillespie; Kishan Dholakia
Journal:  Commun Biol       Date:  2020-05-14

6.  Superfast Synthesis of Stabilized Silver Nanoparticles Using Aqueous Allium sativum (Garlic) Extract and Isoniazid Hydrazide Conjugates: Molecular Docking and In-Vitro Characterizations.

Authors:  Jamal Moideen Muthu Mohamed; Ali Alqahtani; Thankakan Vimala Ajay Kumar; Adel Al Fatease; Taha Alqahtani; Venkatesan Krishnaraju; Fazil Ahmad; Farid Menaa; Ali Alamri; Ranjini Muthumani; Rajendran Vijaya
Journal:  Molecules       Date:  2021-12-24       Impact factor: 4.411

7.  Integrative utility of long read sequencing-based whole genome analysis and phenotypic assay on differentiating isoniazid-resistant signature of Mycobacterium tuberculosis.

Authors:  Ming-Chih Yu; Ching-Sheng Hung; Chun-Kai Huang; Cheng-Hui Wang; Yu-Chih Liang; Jung-Chun Lin
Journal:  J Biomed Sci       Date:  2021-12-18       Impact factor: 8.410

8.  Investigations into Isoniazid Treated Mycobacterium tuberculosis by Electrospray Mass Spectrometry Reveals New Insights into Its Lipid Composition.

Authors:  Rahul Pal; Saif Hameed; Varatharajan Sabareesh; Parveen Kumar; Sarman Singh; Zeeshan Fatima
Journal:  J Pathog       Date:  2018-06-19

Review 9.  Antimicrobial Peptides: a New Frontier in Antifungal Therapy.

Authors:  Giuseppe Buda De Cesare; Shane A Cristy; Danielle A Garsin; Michael C Lorenz
Journal:  mBio       Date:  2020-11-03       Impact factor: 7.867

Review 10.  Drug Discovery for Mycobacterium tuberculosis Using Structure-Based Computer-Aided Drug Design Approach.

Authors:  Murtala A Ejalonibu; Segun A Ogundare; Ahmed A Elrashedy; Morufat A Ejalonibu; Monsurat M Lawal; Ndumiso N Mhlongo; Hezekiel M Kumalo
Journal:  Int J Mol Sci       Date:  2021-12-09       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.